Respicardia
OverviewSuggest Edit
Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time.
| Type | Private | |
| Founded | 2006 | |
| HQ | Hopkins, MN, US | Map |
| Website | respicardia.com |
Latest Updates
| Employees (est.) (Feb 2021) | 80 | (+3%) |
| Cybersecurity rating | B | More |
Key People/Management at Respicardia
B. Kristine Johnson
Director
Peter Sommerness
President and CEO, Director
Tim Hauch
Chief Financial Officer
Kirk Nielsen
Director
Robin Germany
Chief Medical Officer
Jonathan A. Rennert
Director
Respicardia Office Locations
Respicardia has an office in Hopkins
Hopkins, MN, US (HQ)
12400 Whitewater Dr #150
Respicardia Financials and Metrics
Summary Metrics
Founding Date | 2006 |
Respicardia total Funding | $149.1 m |
Respicardia latest funding size | $58.50 m |
Time since last funding | 3 years ago |
Respicardia investors | Polaris Partners, Versant Ventures, Three Arch Partners, Accuitive Medical Ventures, Affinity Capital Management, RK Ventures Group, Sorin Group, Polaris Venture Capital, Abbott, ZOLL Medical Corporation |
Respicardia's latest funding round in December 2017 was reported to be $58.5 m. In total, Respicardia has raised $149.1 m
Respicardia Cybersecurity Score
Respicardia Online and Social Media Presence
Respicardia's Trends
Respicardia News and Updates
January 07, 2021
Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea
MINNETONKA, Minn., Jan. 7, 2021 /PRNewswire/ -- Respicardia, Inc., the manufacturer of the only FDA-approved active implantable system for the treatment of central sleep apnea (CSA), announced today that Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the...
August 06, 2018
CMS Grants New Technology Add-on Payment to the remedē® System for the Treatment of Central Sleep Apnea
MINNETONKA, Minn., Aug. 6, 2018 /PRNewswire/ -- Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) ...
Respicardia Blogs
February 16, 2021
A remedē® PATIENT SINCE 2019, RAY DESCRIBES HIS EXPERIENCE WITH CENTRAL SLEEP APNEA AND HOW HIS LIFE HAS CHANGED AS A RESULT OF SUCCESSFUL TREATMENT.
Ray describes his experience with Central Sleep Apnea (CSA), including his early symptoms, diagnosis, and treatment. He also shares how his life has changed today as a result of successful treatment for his CSA.
The post A <strong>rem</strong>edē® PATIENT SINCE 2019, RAY DESCRIBES HIS EX…
January 07, 2021
remedē® FOR MODERATE TO SEVERE CENTRAL SLEEP APNEA IN ADULTS
Sleep apnea is a sleep breathing disorder that causes you to have interrupted breathing during sleep. This may cause you to sleep poorly, wake up without feeling refreshed, feel fatigued or tired during the day, experience headaches, or feel like you aren’t able to think clearly. Treatment for sleep…
December 09, 2020
UNDERSTANDING THE RELATIONSHIP BETWEEN CENTRAL SLEEP APNEA AND HEART HEALTH
Sleep apnea is very common in patients with heart problems. In fact, it affects up half of patients with heart failure and/or atrial fibrillation.
The post UNDERSTANDING THE RELATIONSHIP BETWEEN CENTRAL SLEEP APNEA AND HEART HEALTH appeared first on Respicardia.
December 07, 2020
CENTRAL SLEEP APNEA (CSA): SYMPTOMS, CAUSES, AND TREATMENT OPTIONS
Central sleep apnea is a form of sleep apnea that is less common and less studied than obstructive sleep apnea. This article explains the differences between central and obstructive sleep apnea, as well as the symptoms, causes, and treatment options for central sleep apnea.
The post CENTRAL SLEEP AP…
December 04, 2020
Novant Health Forsyth Medical Center treats 25th patient with remedē
Respicardia, Inc. announced today that Novant Health Forsyth Medical Center in Winston-Salem, NC has treated its 25th patient with the remedē® System, an implantable device that treats central sleep apnea (CSA) by using phrenic nerve stimulation.
The post Novant Health Forsyth Medical Center treats …
October 20, 2020
Transvenous phrenic nerve stimulation (The remedē System) shows sustained safety and efficacy through 5 years
Trial results showed consistent improvement in sleep disordered breathing, arousals, sleep architecture, and daytime sleepiness through 5 years.
The post Transvenous phrenic nerve stimulation (The remedē System) shows sustained safety and efficacy through 5 years first appeared on Respicardia.
Respicardia Frequently Asked Questions
When was Respicardia founded?
Respicardia was founded in 2006.
Who are Respicardia key executives?
Respicardia's key executives are B. Kristine Johnson, Peter Sommerness and Tim Hauch.
How many employees does Respicardia have?
Respicardia has 80 employees.
Who are Respicardia competitors?
Competitors of Respicardia include AristaMD, Qool Therapeutics and Tactile Medical.
Where is Respicardia headquarters?
Respicardia headquarters is located at 12400 Whitewater Dr #150, Hopkins.
Where are Respicardia offices?
Respicardia has an office in Hopkins.
How many offices does Respicardia have?
Respicardia has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies